BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 15499601)

  • 1. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
    Van Hazel G; Blackwell A; Anderson J; Price D; Moroz P; Bower G; Cardaci G; Gray B
    J Surg Oncol; 2004 Nov; 88(2):78-85. PubMed ID: 15499601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).
    Kemeny NE; Niedzwiecki D; Hollis DR; Lenz HJ; Warren RS; Naughton MJ; Weeks JC; Sigurdson ER; Herndon JE; Zhang C; Mayer RJ
    J Clin Oncol; 2006 Mar; 24(9):1395-403. PubMed ID: 16505413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial comparing weekly bolus 5-fluorouracil plus leucovorin versus monthly 5-day 5-fluorouracil plus leucovorin in metastatic colorectal cancer.
    Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Chen PM
    Hepatogastroenterology; 2000; 47(36):1599-603. PubMed ID: 11149011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response rates.
    Mancini R; Carpanese L; Sciuto R; Pizzi G; Golfieri R; Giampalma L; Cappelli A; Galaverni MC; Blotta A; Fiore F; Izzo F; Lastoria S; Mastro A; Di Marzo M; Cagol PP; Gasparini D; Geatti O; Bacchetti S; Pasqual E; Zeuli M; Paoletti G; Garufi C; Cosimelli M;
    In Vivo; 2006; 20(6A):711-4. PubMed ID: 17203751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases.
    Müller H; Nakchbandi V; Chatzisavvidis I; von Voigt C
    Hepatogastroenterology; 2003; 50(54):1919-26. PubMed ID: 14696433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer.
    Seki H; Ozaki T; Shiina M
    Cardiovasc Intervent Radiol; 2009 Jul; 32(4):679-86. PubMed ID: 19296157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: A Southwest Oncology Group pilot trial.
    Leichman CG; Jacobson JR; Modiano M; Daniels JR; Zalupski MM; Doroshow JH; Fletcher WS; Macdonald JS
    Cancer; 1999 Sep; 86(5):775-81. PubMed ID: 10463975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
    Alberts SR; Horvath WL; Sternfeld WC; Goldberg RM; Mahoney MR; Dakhil SR; Levitt R; Rowland K; Nair S; Sargent DJ; Donohue JH
    J Clin Oncol; 2005 Dec; 23(36):9243-9. PubMed ID: 16230673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
    Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
    Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-arterial infusion of 5-fluorouracil plus granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases.
    Müller H; Nakchbandi W; Chatzissavvidis I; Valek V
    Eur J Surg Oncol; 2001 Nov; 27(7):652-61. PubMed ID: 11669594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Verwaal VJ; Bruin S; Boot H; van Slooten G; van Tinteren H
    Ann Surg Oncol; 2008 Sep; 15(9):2426-32. PubMed ID: 18521686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
    J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
    Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
    J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic arterial infusion combined with oral UFT/UZEL systemic chemotherapy for unresectable liver metastasis of colorectal cancer.
    Tsutsumi S; Yamaguchi S; Tsuboi K; Fukasawa T; Tabe Y; Asao T; Kuwano H
    Hepatogastroenterology; 2008; 55(85):1419-22. PubMed ID: 18795703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer.
    Ducreux M; Ychou M; Laplanche A; Gamelin E; Lasser P; Husseini F; Quenet F; Viret F; Jacob JH; Boige V; Elias D; Delperro JR; Luboinski M;
    J Clin Oncol; 2005 Aug; 23(22):4881-7. PubMed ID: 16009952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
    Shitara K; Munakata M; Muto O; Kasai M; Okada R; Mitobe S; Sakata Y
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1079-84. PubMed ID: 17637544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen.
    Scalamogna R; Brugnatelli S; Tinelli C; Sagrada P; Gattoni E; Tronconi MC; Riccardi A; Luchena G; Corazza GR
    Oncology; 2007; 72(5-6):267-73. PubMed ID: 18187947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.